Cantor Fitzgerald restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report published on Monday, February 5th. Cantor Fitzgerald currently has a $140.00 price objective on the medical equipment provider’s stock. Cantor Fitzgerald also issued estimates for Zimmer Biomet’s FY2018 earnings at $7.68 EPS.
“ZBH received FDA clearance for its Persona cementless knee, earlier than we expected.”,” Cantor Fitzgerald’s analyst wrote.
ZBH has been the subject of a number of other research reports. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet to $125.00 and set an outperform rating for the company in a research report on Tuesday, November 7th. Zacks Investment Research cut shares of Zimmer Biomet from a hold rating to a sell rating in a research report on Monday, November 6th. SunTrust Banks increased their price objective on shares of Zimmer Biomet to $142.00 and gave the stock a buy rating in a research report on Monday, January 29th. BMO Capital Markets lowered their price objective on shares of Zimmer Biomet from $140.00 to $135.00 and set an outperform rating for the company in a research report on Thursday, November 2nd. Finally, Jefferies Group reissued a buy rating and issued a $136.00 price target on shares of Zimmer Biomet in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $141.67.
Shares of Zimmer Biomet (NYSE:ZBH) opened at $116.52 on Monday. The stock has a market cap of $23,565.84, a P/E ratio of 14.49, a PEG ratio of 2.04 and a beta of 1.08. The company has a current ratio of 1.52, a quick ratio of 0.83 and a debt-to-equity ratio of 0.76. Zimmer Biomet has a 1-year low of $108.03 and a 1-year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $2.10. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.14 EPS. research analysts forecast that Zimmer Biomet will post 7.82 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were issued a $0.24 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.82%. Zimmer Biomet’s payout ratio is 10.65%.
A number of large investors have recently made changes to their positions in ZBH. Virtu KCG Holdings LLC raised its stake in Zimmer Biomet by 149.0% during the 2nd quarter. Virtu KCG Holdings LLC now owns 4,407 shares of the medical equipment provider’s stock worth $566,000 after acquiring an additional 2,637 shares in the last quarter. QS Investors LLC raised its stake in Zimmer Biomet by 9.4% during the 2nd quarter. QS Investors LLC now owns 9,326 shares of the medical equipment provider’s stock worth $1,197,000 after acquiring an additional 800 shares in the last quarter. Janus Henderson Group PLC raised its stake in Zimmer Biomet by 100.0% during the 2nd quarter. Janus Henderson Group PLC now owns 135,304 shares of the medical equipment provider’s stock worth $17,372,000 after acquiring an additional 67,657 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Zimmer Biomet by 9.8% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 38,098 shares of the medical equipment provider’s stock worth $4,891,000 after acquiring an additional 3,412 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its stake in Zimmer Biomet by 3.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 22,159 shares of the medical equipment provider’s stock valued at $2,845,000 after purchasing an additional 823 shares during the period. Hedge funds and other institutional investors own 86.36% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/13/zimmer-biomet-zbh-given-buy-rating-at-cantor-fitzgerald.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.